Related Experiment Videos
Agranulocytosis in rheumatoid arthritis associated with long-term flucloxacillin for staphylococcal osteomyelitis
I E Burton1, K M Moussa, P A Sanders
1Department of Haematology, University Hospital of South Manchester, UK.
Abstract:
Agranulocytosis and septicaemia developing in a patient with rheumatoid arthritis after 3 years' intermittent treatment with diclofenac, cimetidine and flucloxacillin for staphylococcal osteomyelitis is described. Treatment with recombinant granulocyte-colony-stimulating factor and high-dose methylprednisolone had no effect on the neutropenia which resolved on stopping all drug therapy. Relapse of agranulocytosis followed reintroduction of flucloxacillin and cimetidine 3 months later.
Insights
A patient with rheumatoid arthritis developed agranulocytosis and septicaemia due to intermittent drug therapy. Neutropenia resolved after discontinuing medications, highlighting potential drug-induced adverse events.
Area of Science:
- Pharmacology
- Rheumatology
- Infectious Diseases
Background:
- Rheumatoid arthritis management often involves multiple medications.
- Staphylococcal osteomyelitis requires prolonged antibiotic treatment.
- Drug-induced agranulocytosis is a rare but serious adverse effect.
Observation:
- A patient with rheumatoid arthritis experienced agranulocytosis and septicaemia.
- This occurred after 3 years of intermittent treatment with diclofenac, cimetidine, and flucloxacillin for staphylococcal osteomyelitis.
- Initial treatment with granulocyte-colony-stimulating factor and methylprednisolone was ineffective.
Findings:
- Neutropenia resolved upon cessation of all drug therapy.
- Agranulocytosis relapsed upon reintroduction of flucloxacillin and cimetidine.
- This suggests a causal link between these medications and the adverse event.
Implications:
- Highlights the importance of vigilant monitoring for drug-induced neutropenia in patients with rheumatoid arthritis.
- Suggests careful consideration of medication choices and duration in complex cases.
- Emphasizes the need for prompt drug withdrawal to manage severe adverse events like agranulocytosis.